Platelet response to serotonin in patients with stable coronary heart disease

Dan A Kim1, Willie G McClure1, Jordan B Neighoff1

  • 1Department of Medicine, Johns Hopkins Medical Institution, Baltimore, Maryland.

Insights

Patients with coronary artery disease (CAD) show unique platelet responses to serotonin (5-HT). High concentrations of 5-HT decreased platelet activation, unlike adenosine diphosphate (ADP), suggesting a link to depression and heart disease mortality.

Area of Science:

  • Cardiovascular Medicine
  • Neuroscience
  • Hematology

Background:

  • Patients with heart disease and depression face higher mortality risks.
  • Serotonergic signaling disruptions are implicated in depression pathophysiology.
  • Platelet function may offer insights into the interplay between heart disease and depression.

Purpose of the Study:

  • To investigate platelet response to serotonin (5-HT) stimulation in patients with stable coronary artery disease (CAD).
  • To explore potential mechanisms linking depression and cardiovascular disease through platelet signaling.

Main Methods:

  • Optical aggregation and flow cytometry were used to measure platelet activation.
  • Platelet responses to increasing concentrations of serotonin (5-HT) and adenosine diphosphate (ADP) were analyzed in 92 stable CAD patients.
  • Epinephrine-augmented 5-HT stimulation was also assessed.

Main Results:

  • Platelet activation and aggregation increased with rising concentrations of adenosine diphosphate (ADP).
  • A significant decrease in platelet activation was observed at the highest serotonin concentration (30 μM) (p=0.005).
  • This paradoxical serotonin response contrasts with the typical ADP-induced platelet activation.

Conclusions:

  • Patients with stable CAD exhibit distinct in vitro platelet activation patterns in response to high-dose serotonin.
  • The underlying mechanisms for this unique 5-HT platelet response in CAD patients remain unclear.
  • Findings may contribute to understanding the complex relationship between heart disease, depression, and platelet function.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
442
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
493